01 3Haemophilia
02 3Haemophilia A
03 2NovoSeven
04 1of which Novoseven
Recombinant Human Coagulation Factor VIIa
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 1,571
2019 Revenue in Millions : 1,672
Growth (%) : -6
Recombinant Human Coagulation Factor VIIa
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 322
2020 Revenue in Millions : 274
Growth (%) : 23
Recombinant Human Coagulation Factor VIIa
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 341
2021 Revenue in Millions : 322
Growth (%) : 6
Recombinant Human Coagulation Factor VIIa
Main Therapeutic Indication : Rare Diseases
Currency : USD
2023 Revenue in Millions : 352
2022 Revenue in Millions : 341
Growth (%) : 4
Recombinant Coagulation Factor VIIa
Main Therapeutic Indication : Rare Diseases
Currency : USD
2023 Revenue in Millions : 1,157
2022 Revenue in Millions : 1,212
Growth (%) : -4
Recombinant Coagulation Factor VIIa
Main Therapeutic Indication : Rare Diseases and Disorders
Currency : USD
2024 Revenue in Millions : 1,107
2023 Revenue in Millions : 1,157
Growth (%) : -4
Recombinant Human Coagulation Factor VIIa
Main Therapeutic Indication : Blood Disorders
Currency : USD
2018 Revenue in Millions : 1,436
2017 Revenue in Millions : 1,570
Growth (%) : -9%
Coagulation Factor VII [Recombinant]
Main Therapeutic Indication : Blood Disorders
Currency : USD
2018 Revenue in Millions : 1,182
2017 Revenue in Millions : 1,381
Growth (%) : -14%
Recombinant Human Coagulation Factor VIIa
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 1,542
2018 Revenue in Millions : 1,436
Growth (%) : 7
